Division of Plastic and Reconstructive Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA.
Aesthet Surg J. 2013 Mar;33(3):378-86. doi: 10.1177/1090820X13478819. Epub 2013 Feb 25.
As elective nonreconstructive breast surgery increases in popularity, there is greater demand for accurate multi-institutional data on minor and major postoperative complications.
The authors utilized a multi-institutional database to compare 30-day morbidities and reoperation rates among the different types of elective nonreconstructive breast surgery.
Patients in the National Surgical Quality Improvement Program (NSQIP) participant use file who underwent elective nonreconstructive breast surgery between 2006 and 2010 were identified. Twenty defined morbidities were compared among mastopexy, reduction mammaplasty, and augmentation mammaplasty patients using analysis of variance and χ(2) tests for continuous variables and categorical variables, respectively. Logistic regression modeling was employed to identify preoperative risk factors for complications.
Of the 3612 patients identified, 380 underwent mastopexy, 2507 underwent reduction mammaplasty, and 725 underwent augmentation mammaplasty. Complication rates were low in all cohorts, and patients undergoing augmentation mammaplasty had the lowest overall complication rate compared with mastopexy and reduction mammaplasty (1.24%, 2.37%, and 4.47%). Patients undergoing reduction mammaplasty had a modestly elevated incidence of overall morbidity, superficial surgical site infections, and wound disruptions (P < .05). Moreover, 30-day reoperation rates for mastopexy, reduction mammaplasty, and augmentation mammaplasty were low (1.58%, 2.07%, and 0.97%), as were the rates of life-threatening complications (0%, 0.16%, and 0%). One death was observed for all 3612 procedures (0.03%).
Elective breast surgery is a safe procedure with an extremely low incidence of life-threatening complications and mortality. Comprehensive data collated from the NSQIP initiative add to the literature, and the findings of this multi-institutional study may help further guide patient education and expectations on potentially deleterious outcomes.
随着择期非重建性乳房手术的日益普及,人们对轻微和重大术后并发症的准确多机构数据的需求也越来越大。
作者利用多机构数据库比较了不同类型的择期非重建性乳房手术的 30 天发病率和再次手术率。
在国家外科质量改进计划(NSQIP)参与者使用文件中确定了 2006 年至 2010 年间接受择期非重建性乳房手术的患者。使用方差分析和 χ(2)检验比较乳房提升术、乳房缩小术和乳房增大术患者的 20 种定义性并发症,分别用于连续变量和分类变量。采用 logistic 回归模型识别并发症的术前危险因素。
在 3612 例患者中,380 例接受乳房提升术,2507 例接受乳房缩小术,725 例接受乳房增大术。所有组的并发症发生率均较低,与乳房提升术和乳房缩小术相比,乳房增大术患者的总体并发症发生率最低(1.24%、2.37%和 4.47%)。乳房缩小术患者的总体发病率、浅表手术部位感染和伤口破裂略有升高(P <.05)。此外,乳房提升术、乳房缩小术和乳房增大术的 30 天再次手术率均较低(1.58%、2.07%和 0.97%),危及生命的并发症发生率也较低(0%、0.16%和 0%)。所有 3612 例手术均观察到 1 例死亡(0.03%)。
择期乳房手术是一种安全的手术,危及生命的并发症和死亡率极低。从 NSQIP 计划中综合收集的数据增加了文献内容,这项多机构研究的结果可能有助于进一步指导患者教育和对潜在有害结果的期望。